Silo Pharma amends license milestones with University of Maryland, Baltimore

Silo Pharma, Inc.

Fourth Amendment replaces Schedule C diligence milestones under the Master License Agreement.
New milestones include completing in vitro peptide binding by March 2025 and preclinical studies by September 2025.
IND filing for a Licensed Product due by February 2028; first commercial sale by February 2034.
All other terms, including royalty rate and payment obligations, remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.